Net income
-85.8 million USD
2025-07-01 – 2026-06-30
Fundies. English
LB Pharmaceuticals Inc
EDGAR7 filing records in this dataset, filed from 2025-08-22 to 2026-08-11. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 283 million USD Source
Exact value
283111000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 28.7 million shares Source
Exact value
28681063 shares
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-11.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- operating income: No compatible figures in this window
- Net income: 2 of 11 periods available· newest 2025-12-31
- Operating cash flow: 2 of 11 periods available· newest 2025-12-31
- Capital expenditure: 2 of 11 periods available· newest 2025-12-31
- Total assets: 2 of 11 periods available· newest 2025-12-31
- Total liabilities: 2 of 11 periods available· newest 2025-12-31
- Current assets: 2 of 11 periods available· newest 2025-12-31
- Current liabilities: 2 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 2 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 2 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
+USD 37.9 millionPrior period
−USD 63.1 million
–
Current period
−USD 25.2 million
–
Exact inputs and evidence
-25200000 − -63102000 = 37902000 USD
-63102000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-25200000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 17.85 millionPrior period
−USD 53.05 million
–
Current period
−USD 35.2 million
–
Exact inputs and evidence
-35200000 − -53052000 = 17852000 USD
-53052000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-35200000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-93.2%Prior period
USD 769,000
–
Current period
USD 52,000
–
Exact inputs and evidence
52000 − 769000 = -717000 USD
769000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source52000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | −USD 63.1 million Exact valueExact value: -63102000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 53.05 million Exact valueExact value: -53052000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 769,000 Exact valueExact value: 769000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 53.82 million Calculation and evidence-53052000 − 769000 USD Exact free cash flow: -53821000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 25.2 million Exact valueExact value: -25200000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 35.2 million Exact valueExact value: -35200000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 52,000 Exact valueExact value: 52000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 35.25 million Calculation and evidence-35200000 − 52000 USD Exact free cash flow: -35252000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
7 filings · 377 latest values · 377 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001691082, 1691082, LBRX, edgar:1691082
Also known as LB PHARMACEUTICALS INC, LB PHARMACEUTICALS INC., LB Pharmaceuticals Inc